Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD
- PMID: 35443531
Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD
Abstract
Non -alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease throughout the world. The spectrum of NAFLD includes a non-serious condition called fatty liver, a more serious condition named non-alcoholic steatohepatitis (NASH) which may lead to severe liver scarring and cirrhosis. Obesity and diabetes mellitus are established risk factors for NAFLD. However, it has been increasingly reported among lean or non-obese and non diabetic patients. The aim of this study was to evaluate the magnitude, clinical and metabolic profiles of NAFLD in normal body mass index (BMI) subjects, defined as lean NAFLD, as compared to overweight or obese NAFLD and lean healthy controls.
Material: 92 consecutive NAFLD and 90 healthy controls were studied between 2021 March to 2021 August, for a period of 6 months. Patients of NAFLD were diagnosed on the basis of ultrasonography features, presence of metabolic syndrome or insulin resistance. Patients with a BMI of less than 23 kg/m2 were defined as lean NAFLD. Alcoholic patients, those with liver diseases of other known causes, patients on medications known to induce fatty liver were excluded. For comparing the characteristics of lean NAFLD patients, we also included 90 lean healthy subjects with normal liver on ultrasonography as control subjects.
Observation: Among the 92 NAFLD patients, 18 (19.56%) were lean or non-obese, while 48 (52.17%) were obese, and 26 (28.26%) were overweight. The lean NAFLD cohort was younger (p<0.001), more commonly female, had a lower prevalence of diabetes (p=0.01) and metabolic syndrome (p<0.001). The serum lipid profile was similar in all the three BMI categories and 82% of the lean NAFLD were dyslipidemic. In comparison to obese subjects, patients with lean NAFLD had significantly less fibrosis. Despite being lean, the mean BMI of lean NAFLD patients was still higher than healthy control group.
Conclusion: Dyslipidemia is frequently associated with lean NAFLD. Lean NAFLD when compared to obese or overweight NAFLD, have lower prevalence of type 2 diabetes mellitus, metabolic syndrome and less fibrosis on fibroscan of liver. They donot have abdominal obesity, but their BMI was higher than healthy controls.
© Journal of the Association of Physicians of India 2011.
Similar articles
-
Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.Obes Facts. 2023;16(5):427-434. doi: 10.1159/000530845. Epub 2023 May 22. Obes Facts. 2023. PMID: 37231905 Free PMC article.
-
Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?Indian J Endocrinol Metab. 2013 Jul;17(4):665-71. doi: 10.4103/2230-8210.113758. Indian J Endocrinol Metab. 2013. PMID: 23961483 Free PMC article.
-
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.World J Gastroenterol. 2014 Dec 21;20(47):17932-40. doi: 10.3748/wjg.v20.i47.17932. World J Gastroenterol. 2014. PMID: 25548491 Free PMC article.
-
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36400097
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
Cited by
-
Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.Obes Facts. 2023;16(5):427-434. doi: 10.1159/000530845. Epub 2023 May 22. Obes Facts. 2023. PMID: 37231905 Free PMC article.
-
Naringin ameliorates high-fat diet-induced hepatotoxicity and dyslipidemia in experimental rat model via modulation of anti-oxidant enzymes, AMPK and SERBP-1c signaling pathways.Toxicol Rep. 2025 May 30;14:102062. doi: 10.1016/j.toxrep.2025.102062. eCollection 2025 Jun. Toxicol Rep. 2025. PMID: 40520525 Free PMC article.
-
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic.World J Hepatol. 2024 Apr 27;16(4):511-516. doi: 10.4254/wjh.v16.i4.511. World J Hepatol. 2024. PMID: 38689742 Free PMC article.
-
The Related Metabolic Diseases and Treatments of Obesity.Healthcare (Basel). 2022 Aug 25;10(9):1616. doi: 10.3390/healthcare10091616. Healthcare (Basel). 2022. PMID: 36141228 Free PMC article. Review.
-
Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications.J Clin Transl Hepatol. 2024 Jan 28;12(1):70-78. doi: 10.14218/JCTH.2023.00252. Epub 2023 Aug 25. J Clin Transl Hepatol. 2024. PMID: 38250459 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Medical